Tazomac-composition, description, pharmacological action, adverse effects, dosage, storage, alternative brands, images, precaution
Tazomac
COMPOSITION:
Tazomac 2.25gm
Each vial contain;
Piperacillin sodium. 2.0gm
Tazobactam sodium. 0.25gm
Tazomac 4.5gm
Each vial contain;
Piperacillin sodium. 4.0gm
Tazobactam sodium. 0.5gm
DESCRIPTION:
Piperacillin-Tazobactam is an injectable antibacterial combination product consisting of the semisynthetic antibiotic piperacillin sodium and the beta-lactamase inhibitor Tazobactam sodium for intravenous administration. Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to piperacillin binding proteins. Tazobactam is a beta-lactamase inhibitor.
PHARMACOLOGICAL ACTION
Mechanism / Pharmacodynamic:
Piperacillin exerts bactericidal activity by inhibition of septum and cell wall synthesis. Tazobactum, a beta-lactam structurally related to penicillin, is an inhibitor of many beta-lactamases, which commonly cause resistance to penicillins and cephalosporins, but it does not inhibit AmpC enzyme or Metallo beta-lactamases. Tazobactam extends the antibiotic spectrum of piperacillin to include many beta-lactamase-producing bacteria that have acquired resistance to piperacillin alone.
Pharmacokinetic:
Absorption- The peak piperacillin and tazobactam concentration after 4g/0.5g administered over 30 minutes by intravenous infusion are 298microgram/ml and 34microgram/ml respectively.
Distribution-Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of tazobactam metabolite is negligible. Piperacillin / Tazobactam is widely distributed in tissues and body fluid including intestinal mucosa, gall bladder, lungs, bile, and bone. Mean tissue concentration is generally 50 to 100% of those in plasma. Distribution into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins.
Biotransformation- Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that has been found to be microbiologically inactive.
Elimination- Piperacillin, and Tazobactam are eliminated in the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as an unchanged substance, with 68% of the administered dose appearing in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion, with 80% of the administered dose.
ADVERSE REACTION:
2.Constipation
3.Nausea
4.Vomiting
5.Heartburn
6.Stomach pain
7.Fever
8.Headache
9.Mouth sores
10. Difficulty falling asleep or staying asleep
11.Rash
12.Itching
13.Hives
14.Difficulty breathing or swallowing
15.wheezing
SPECIAL PRECAUTION:
- Before using piperacillin and tazobactam injection to inform your doctor and pharmacist if you are allergic to piperacillin, tazobactam, cephalosporin antibiotics such as cefaclor, cefadroxil, cefuroxime and beta-lactam antibiotics such as penicillin r amoxicillin .
- To inform your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to ta.
- To inform your doctor if you have kidney dise e.
- To inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
- if you are having dental surg y, to inform the doctor or dentist that you are receiving piperacillin and tazobactam injection.
STORAGE:
Temperature 15 -30-degree celsius.
Comments
Post a Comment